Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Effect of Androgen-Deprivation Therapy on Bone Mineral Density in Patients with Prostate Cancer: A Systematic Review and Meta-Analysis.

Kim DK, Lee JY, Kim KJ, Hong N, Kim JW, Hah YS, Koo KC, Kim JH, Cho KS.

J Clin Med. 2019 Jan 18;8(1). pii: E113. doi: 10.3390/jcm8010113.

2.

Effect of Androgen Deprivation Therapy on Bone Mineral Density in a Prostate Cancer Cohort in New Zealand: A Pilot Study.

Wang A, Karunasinghe N, Plank L, Zhu S, Osborne S, Bishop K, Brown C, Schwass T, Masters J, Holmes M, Huang R, Keven C, Ferguson L, Lawrenson R.

Clin Med Insights Oncol. 2017 Oct 9;11:1179554917733449. doi: 10.1177/1179554917733449. eCollection 2017.

3.

Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial.

Uth J, Hornstrup T, Christensen JF, Christensen KB, Jørgensen NR, Schmidt JF, Brasso K, Jakobsen MD, Sundstrup E, Andersen LL, Rørth M, Midtgaard J, Krustrup P, Helge EW.

Osteoporos Int. 2016 Apr;27(4):1507-1518. doi: 10.1007/s00198-015-3399-0. Epub 2015 Nov 16.

PMID:
26572756
4.

Changes in bone mineral density in men starting androgen deprivation therapy and the protective role of vitamin D.

Alibhai SM, Mohamedali HZ, Gulamhusein H, Panju AH, Breunis H, Timilshina N, Fleshner N, Krahn MD, Naglie G, Tannock IF, Tomlinson G, Warde P, Duff Canning S, Cheung AM.

Osteoporos Int. 2013 Oct;24(10):2571-9. doi: 10.1007/s00198-013-2343-4. Epub 2013 Apr 6.

PMID:
23563932
5.
6.

Evaluation of Bone Turnover / Quality Markers and Bone Mineral Density in Prostate Cancer Patients Receiving Androgen Deprivation Therapy with or without Denosumab.

Miyazawa Y, Sekine Y, Syuto T, Nomura M, Koike H, Matsui H, Shibata Y, Ito K, Suzuki K.

Anticancer Res. 2017 Jul;37(7):3667-3671.

PMID:
28668858
7.

Utilization of DXA Bone Mineral Densitometry in Ontario: An Evidence-Based Analysis.

Medical Advisory Secretariat.

Ont Health Technol Assess Ser. 2006;6(20):1-180. Epub 2006 Nov 1.

8.

Effect of Diphosphonates on Bone Mineral Density in Men Receiving Androgen Deprivation Therapy for Prostate Cancer.

Wu C, Chen W, Huang X, Lin R, Wu J, Zhang X.

Clin Genitourin Cancer. 2018 Dec;16(6):e1243-e1250. doi: 10.1016/j.clgc.2018.07.016. Epub 2018 Jul 21. Review.

PMID:
30146230
9.

Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy.

Wang W, Yuasa T, Tsuchiya N, Maita S, Kumazawa T, Inoue T, Saito M, Ma Z, Obara T, Tsuruta H, Satoh S, Habuchi T.

Endocr Relat Cancer. 2008 Dec;15(4):943-52. doi: 10.1677/ERC-08-0116. Epub 2008 Jul 30.

PMID:
18667685
10.

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

Kiratli BJ, Srinivas S, Perkash I, Terris MK.

Urology. 2001 Jan;57(1):127-32.

PMID:
11164157
11.
12.

Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer.

Greenspan SL, Coates P, Sereika SM, Nelson JB, Trump DL, Resnick NM.

J Clin Endocrinol Metab. 2005 Dec;90(12):6410-7. Epub 2005 Sep 27.

PMID:
16189261
13.

Decrease of bone mineral density in Japanese patients with non-metastatic prostate cancer treated with androgen deprivation therapy.

Kato S, Kawase M, Kato D, Ishida T, Uno M, Fujimoto Y, Masue T, Masue N, Deguchi T.

J Bone Miner Metab. 2019 Jan;37(1):72-80. doi: 10.1007/s00774-017-0897-5. Epub 2018 Jan 8.

PMID:
29313098
14.

Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.

Preston DM, Torréns JI, Harding P, Howard RS, Duncan WE, McLeod DG.

Prostate Cancer Prostatic Dis. 2002;5(4):304-10.

15.

Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis.

Planas J, Trilla E, Raventós C, Cecchini L, Orsola A, Salvador C, Placer J, Encabo G, Morote J.

BJU Int. 2009 Dec;104(11):1637-40. doi: 10.1111/j.1464-410X.2009.08622.x. Epub 2009 Jun 22.

16.

Randomized, double-blinded, placebo-controlled, trial of risedronate for the prevention of bone mineral density loss in nonmetastatic prostate cancer patients receiving radiation therapy plus androgen deprivation therapy.

Choo R, Lukka H, Cheung P, Corbett T, Briones-Urbina R, Vieth R, Ehrlich L, Kiss A, Danjoux C.

Int J Radiat Oncol Biol Phys. 2013 Apr 1;85(5):1239-45. doi: 10.1016/j.ijrobp.2012.11.007. Epub 2012 Dec 19.

PMID:
23265571
17.

Single infusion of zoledronic acid to prevent androgen deprivation therapy-induced bone loss in men with hormone-naive prostate carcinoma.

Satoh T, Kimura M, Matsumoto K, Tabata K, Okusa H, Bessho H, Iwamura M, Ishiyama H, Hayakawa K, Baba S.

Cancer. 2009 Aug 1;115(15):3468-74. doi: 10.1002/cncr.24404.

18.

Androgen deprivation therapy for prostate cancer results in significant loss of bone density.

Wei JT, Gross M, Jaffe CA, Gravlin K, Lahaie M, Faerber GJ, Cooney KA.

Urology. 1999 Oct;54(4):607-11.

PMID:
10510915
19.

[Influence of androgen deprivation therapy on bone mineral density in men with prostate cancer].

Deng J, Li W, Yang L, Wang L, Zou D.

Zhonghua Nan Ke Xue. 2004 Oct;10(10):761-3. Chinese.

PMID:
15562791
20.

Long-term effects of androgen deprivation therapy in prostate cancer patients.

Basaria S, Lieb J 2nd, Tang AM, DeWeese T, Carducci M, Eisenberger M, Dobs AS.

Clin Endocrinol (Oxf). 2002 Jun;56(6):779-86.

PMID:
12072048

Supplemental Content

Support Center